Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.78 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.78 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29610430 | 0.92 | OPRM1 (0.77) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL22959877 | 0.92 | OPRM1 (0.77) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL10329433 | 0.92 | OPRM1 (0.73) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL13250907 | 0.91 | OPRM1 (0.84) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL13998951 | 0.90 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL16922125 | 0.90 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL3476558 | 0.90 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL3477727 | 0.90 | OPRM1 (0.73) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL7770909 | 0.89 | OPRM1 (0.71) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL7775794 | 0.89 | OPRM1 (0.71) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362071-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Grünenthal GmbH (DE) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017049294-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2011097269-A9 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| EP-2531200-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Thar Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097269-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |